<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280695</url>
  </required_header>
  <id_info>
    <org_study_id>MSDC-0602-C002</org_study_id>
    <nct_id>NCT01280695</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metabolic Solutions Development Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metabolic Solutions Development Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of MSDC-0602 and to
      evaluate the reduction in fasting plasma glucose in patients with Type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>To characterize the reduction in fasting plasma glucose in response to three different doses of MSDC-0602 Tablets as compared to placebo following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>To explore the drug effect difference in the reduction in hemoglobin A1c in response to three different doses of MSDC-0602 and pioglitazone (45 mg Actos®) as compared to placebo following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>To characterize the effects of three different doses of MSDC-0602 and pioglitazone as compared to placebo on hematocrit, body weight, and edema following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematocrit</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>To characterize the effects of three different doses of MSDC-0602 and pioglitazone as compared to placebo in hematocrit following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Insulin</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>To characterize the effects of 3 different doses of MSDC-0602 and pioglitazone as compared to placebo on insulin following once-daily dosing for 28 consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Molecular Weight Adiponectin</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>To evaluate the effects of three different doses of MSDC-0602 and pioglitazone as compared to placebo on biomarkers of inflammatory status (high molecular weight adiponectin) following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSDC-0602 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MSDC-0602 capsule 100 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSDC-0602 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MSDC-0602 capsule 250 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSDC-0602 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MSDC-0602 capsule 500 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone 45 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone capsule 45 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSDC-0602 100 mg</intervention_name>
    <description>MSDC-0602 100 mg Capsules</description>
    <arm_group_label>MSDC-0602 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSDC-0602 250 mg</intervention_name>
    <description>MSDC-0602 250 mg Capsules</description>
    <arm_group_label>MSDC-0602 250 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSDC-0602 250 mg</intervention_name>
    <description>MSDC-0602 500 mg Capsules</description>
    <arm_group_label>MSDC-0602 500 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone 45 mg Capsules</description>
    <arm_group_label>Pioglitazone 45 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients must meet all of the following inclusion criteria to be eligible for enrollment
        into the study:

        Inclusion Criteria:

          1. Males and females with Type 2 diabetes (fasting plasma glucose ≥126 mg/dL at
             screening, glycosylated hemoglobin [HbA1c] &gt;7 and ≤10%, and Insulin C-peptide &gt;1
             ng/mL). Patients can be naïve to diabetes therapy or if taking metformin should be on
             a stable dose level for a period of at least 3 months prior to screening visit (no
             dose limit).

          2. Between the ages of 18-75 years, inclusive.

          3. Females should be either postmenopausal (at least 12 months since last menses) or
             surgically sterilized (bilateral tubal ligation or hysterectomy). Menopausal status
             will be verified by a follicle-stimulating hormone (FSH) test. If FSH levels are below
             40 mIU/mL, some method of birth control must be used. Those with bilateral tubal
             ligation must also use a barrier method of birth control. In addition, all females
             must have a negative pregnancy test at Screen and Day 15 regardless of childbearing
             potential. For postmenopausal women only, if FSH levels are above 40 mIU/mL and serum
             pregnancy results are indeterminant, the subject will be assessed as not pregnant.

             Males with female partners of child-bearing potential must agree to use adequate
             contraceptive methods (including a condom, plus one other form of contraception) if
             engaging in sexual intercourse.

          4. Body Mass Index (BMI) ≥ 25 kg/m2 and ≤ 45 kg/m2 (inclusive).

          5. Willing and able to make a screening visit to the clinic and six visits over a 10 week
             period.

          6. Willing and able to sign an informed consent document indicating understanding the
             purpose of and procedures required for the study and willingness to participate in the
             study.

        Subject Exclusion Criteria:

          1. Use of TZDs or diabetes medications other than metformin (generic or Glucophage®) 3
             months prior to screening.

          2. History of diabetic ketoacidosis or hyperosmolar non-ketotic coma.

          3. Fasting plasma glucose in excess of 240 mg/dl at screening

          4. History of heart failure (including CHF) or previous cardiovascular event (myocardial
             infarct, by-pass surgery, or PTCA) within the past 6 months prior to screening.

          5. ALT and/or AST levels that equal or exceed twice the upper limit of normal; bilirubin
             levels that exceed 2 mg/dL; serum creatinine &gt;1.5 mg/dL in men or &gt; 1.4 mg/dL in
             women.

          6. History of nephropathy, neuropathy, or retinopathy within 6 months of screening.

          7. Use of glucocorticoids (oral, injectible, intraarticular, or chronic inhaled) or
             weight-loss drugs within 3 months of randomization.

          8. Current or recurrent disease that may affect the action, absorption or disposition of
             the study treatment, or clinical or laboratory assessments.

          9. Current or history of severe or unstable disorder (medical or psychiatric) requiring
             treatment that may make the patient unlikely to complete the study.

         10. Febrile illness within the 5 days prior to Visit 1.

         11. Known history of HIV, hepatitis B, or hepatitis C.

         12. Clinically significant findings on physical examination, including BP, pulse rate and
             12-lead ECG.

         13. Blood pressure greater than 160/100 mmHg. Patients with elevated BP (&lt;160/100 mmHg)
             with or without current treatment will be allowed at the discretion of the Principal
             Investigator (PI) and primary care physician. Individuals with hypertension must have
             been stabilized to the current treatment regimen for at least 6 weeks prior to
             screening.

         14. Change in BP or lipid-lowering medication within 6 weeks or change in dose of
             metformin or thyroid replacement within 3 months prior to screening.

         15. Known or suspected intolerance or hypersensitivity to the study drugs, closely related
             compounds or any of their stated ingredients.

         16. History of alcohol or drug abuse within 6 months of Screening.

         17. Have participated in an investigational study or received an investigational drug
             within 30 days or 5 half-lives (whichever is longer) prior to study drug
             administration.

         18. Blood donation of 1 pint or more within 56 days of screening.

         19. Plasmapheresis or plasma donation within 30 days of screening.

         20. Single 12-lead ECG demonstrating a QTcB &gt;450 msec at Screening. A single repeat ECG
             may be done at the Investigator's discretion.

         21. Any surgical or medical condition which may significantly alter the absorption of any
             drug substance including, but not limited to, any of the following: history of major
             gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel
             resection, gastric bypass, gastric stapling, or gastric banding, currently active
             inflammatory bowel syndrome.

         22. Evidence of clinically relevant pathology that could interfere with the study results
             or put the patient's safety at risk.

         23. Malignancy, including leukemia and lymphoma (not including basal cell skin cancer)
             within the last 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Colca, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Metabolic Solutions Development Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2011</study_first_submitted>
  <study_first_submitted_qc>January 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2011</study_first_posted>
  <results_first_submitted>October 30, 2013</results_first_submitted>
  <results_first_submitted_qc>October 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 20, 2013</results_first_posted>
  <last_update_submitted>March 17, 2014</last_update_submitted>
  <last_update_submitted_qc>March 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes</keyword>
  <keyword>High blood sugar</keyword>
  <keyword>Blood sugar</keyword>
  <keyword>Blood glucose</keyword>
  <keyword>Glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 15 investigational sites between February 15, 2011 and July 6, 2011.</recruitment_details>
      <pre_assignment_details>This study consisted of a 14-day placebo lead-in period and a 28-day double-blind treatment period. Eligible patients were randomized following the lead-in period based on a stratification criterion of current metformin use (yes, no) to one of the 5 treatments: MSDC 0602 100 mg, MSDC-0602 250 mg, MSDC-0602 500 mg, pioglitazone 45 mg, or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo capsule once daily</description>
        </group>
        <group group_id="P2">
          <title>MSDC-0602 100 mg</title>
          <description>MSDC-0602 capsule 100 mg once daily</description>
        </group>
        <group group_id="P3">
          <title>MSDC-0602 250 mg</title>
          <description>MSDC-0602 capsule 250 mg once daily</description>
        </group>
        <group group_id="P4">
          <title>MSDC-0602 500 mg</title>
          <description>MSDC-0602 capsule 500 mg once daily</description>
        </group>
        <group group_id="P5">
          <title>Pioglitazone 45 mg</title>
          <description>Pioglitazone capsule 45 mg once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo capsule once daily</description>
        </group>
        <group group_id="B2">
          <title>MSDC-0602 100 mg</title>
          <description>MSDC-0602 capsule 100 mg once daily</description>
        </group>
        <group group_id="B3">
          <title>MSDC-0602 250 mg</title>
          <description>MSDC-0602 capsule 250 mg once daily</description>
        </group>
        <group group_id="B4">
          <title>MSDC-0602 500 mg</title>
          <description>MSDC-0602 capsule 500 mg once daily</description>
        </group>
        <group group_id="B5">
          <title>Pioglitazone 45 mg</title>
          <description>Pioglitazone capsule 45 mg once daily</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="26"/>
            <count group_id="B6" value="129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.2" spread="8.87"/>
                    <measurement group_id="B2" value="57.6" spread="8.07"/>
                    <measurement group_id="B3" value="57.7" spread="7.35"/>
                    <measurement group_id="B4" value="55.5" spread="8.59"/>
                    <measurement group_id="B5" value="55.7" spread="8.01"/>
                    <measurement group_id="B6" value="56.7" spread="8.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Fasting Plasma Glucose</title>
        <description>To characterize the reduction in fasting plasma glucose in response to three different doses of MSDC-0602 Tablets as compared to placebo following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>Per-Protocol Population:Included all patients who completed the 4-week, double blind treatment period without any major deviations from the protocol procedures. The Per-Protocol Population was used for all efficacy measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0602 100 mg</title>
            <description>MSDC-0602 capsule 100 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>MSDC-0602 250 mg</title>
            <description>MSDC-0602 capsule 250 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>MSDC-0602 500 mg</title>
            <description>MSDC-0602 capsule 500 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 45 mg</title>
            <description>Pioglitazone capsule 45 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose</title>
          <description>To characterize the reduction in fasting plasma glucose in response to three different doses of MSDC-0602 Tablets as compared to placebo following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.</description>
          <population>Per-Protocol Population:Included all patients who completed the 4-week, double blind treatment period without any major deviations from the protocol procedures. The Per-Protocol Population was used for all efficacy measurements.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="8.90" lower_limit="-12.0" upper_limit="26.0"/>
                    <measurement group_id="O2" value="-0.5" spread="9.77" lower_limit="-34.0" upper_limit="19.0"/>
                    <measurement group_id="O3" value="-20.0" spread="10.06" lower_limit="-32.0" upper_limit="20.0"/>
                    <measurement group_id="O4" value="-16.0" spread="9.68" lower_limit="-37.0" upper_limit="10.0"/>
                    <measurement group_id="O5" value="-22.0" spread="9.38" lower_limit="-47.0" upper_limit="-4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4195</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-10.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.0</ci_lower_limit>
            <ci_upper_limit>14.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0811</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-18.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.0</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0639</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-20.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.0</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-32.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.0</ci_lower_limit>
            <ci_upper_limit>-12.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c</title>
        <description>To explore the drug effect difference in the reduction in hemoglobin A1c in response to three different doses of MSDC-0602 and pioglitazone (45 mg Actos®) as compared to placebo following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>The Per-Protocol Population included all patients who completed the 4-week, double blind treatment period without any major deviations from the protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0602 100 mg</title>
            <description>MSDC-0602 capsule 100 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>MSDC-0602 250 mg</title>
            <description>MSDC-0602 capsule 250 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>MSDC-0602 500 mg</title>
            <description>MSDC-0602 capsule 500 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 45 mg</title>
            <description>Pioglitazone capsule 45 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c</title>
          <description>To explore the drug effect difference in the reduction in hemoglobin A1c in response to three different doses of MSDC-0602 and pioglitazone (45 mg Actos®) as compared to placebo following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.</description>
          <population>The Per-Protocol Population included all patients who completed the 4-week, double blind treatment period without any major deviations from the protocol procedures.</population>
          <units>percentage of hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.081"/>
                    <measurement group_id="O2" value="0.09" spread="0.088"/>
                    <measurement group_id="O3" value="-0.10" spread="0.090"/>
                    <measurement group_id="O4" value="-0.17" spread="0.088"/>
                    <measurement group_id="O5" value="-0.14" spread="0.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight</title>
        <description>To characterize the effects of three different doses of MSDC-0602 and pioglitazone as compared to placebo on hematocrit, body weight, and edema following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>The Per-Protocol Population included all patients who completed the 4-week, double blind treatment period without any major deviations from the protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0602 100 mg</title>
            <description>MSDC-0602 capsule 100 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>MSDC-0602 250 mg</title>
            <description>MSDC-0602 capsule 250 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>MSDC-0602 500 mg</title>
            <description>MSDC-0602 capsule 500 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 45 mg</title>
            <description>Pioglitazone capsule 45 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight</title>
          <description>To characterize the effects of three different doses of MSDC-0602 and pioglitazone as compared to placebo on hematocrit, body weight, and edema following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.</description>
          <population>The Per-Protocol Population included all patients who completed the 4-week, double blind treatment period without any major deviations from the protocol procedures.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.267"/>
                    <measurement group_id="O2" value="0.25" spread="0.291"/>
                    <measurement group_id="O3" value="-0.07" spread="0.297"/>
                    <measurement group_id="O4" value="0.17" spread="0.290"/>
                    <measurement group_id="O5" value="0.54" spread="0.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematocrit</title>
        <description>To characterize the effects of three different doses of MSDC-0602 and pioglitazone as compared to placebo in hematocrit following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>The Per-Protocol Population included all patients who completed the 4-week, double blind treatment period without any major deviations from the protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0602 100 mg</title>
            <description>MSDC-0602 capsule 100 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>MSDC-0602 250 mg</title>
            <description>MSDC-0602 capsule 250 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>MSDC-0602 500 mg</title>
            <description>MSDC-0602 capsule 500 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 45 mg</title>
            <description>Pioglitazone capsule 45 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematocrit</title>
          <description>To characterize the effects of three different doses of MSDC-0602 and pioglitazone as compared to placebo in hematocrit following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.</description>
          <population>The Per-Protocol Population included all patients who completed the 4-week, double blind treatment period without any major deviations from the protocol procedures.</population>
          <units>Change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.36"/>
                    <measurement group_id="O2" value="-0.9" spread="0.39"/>
                    <measurement group_id="O3" value="-1.2" spread="0.40"/>
                    <measurement group_id="O4" value="-1.7" spread="0.39"/>
                    <measurement group_id="O5" value="-1.4" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Insulin</title>
        <description>To characterize the effects of 3 different doses of MSDC-0602 and pioglitazone as compared to placebo on insulin following once-daily dosing for 28 consecutive days</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>The Per-Protocol population included all patients who completed the 4-week, double blind treatment period without any major deviations from the protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0602 100 mg</title>
            <description>MSDC-0602 capsule 100 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>MSDC-0602 250 mg</title>
            <description>MSDC-0602 capsule 250 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>MSDC-0602 500 mg</title>
            <description>MSDC-0602 capsule 500 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 45 mg</title>
            <description>Pioglitazone capsule 45 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Insulin</title>
          <description>To characterize the effects of 3 different doses of MSDC-0602 and pioglitazone as compared to placebo on insulin following once-daily dosing for 28 consecutive days</description>
          <population>The Per-Protocol population included all patients who completed the 4-week, double blind treatment period without any major deviations from the protocol procedures.</population>
          <units>µIU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="1.434"/>
                    <measurement group_id="O2" value="-1.70" spread="1.561"/>
                    <measurement group_id="O3" value="-1.11" spread="1.601"/>
                    <measurement group_id="O4" value="-2.13" spread="1.564"/>
                    <measurement group_id="O5" value="-3.21" spread="1.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Molecular Weight Adiponectin</title>
        <description>To evaluate the effects of three different doses of MSDC-0602 and pioglitazone as compared to placebo on biomarkers of inflammatory status (high molecular weight adiponectin) following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>The Per-Protocol Population included all patients who completed the 4-week, double blind treatment period without any major deviations from the protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0602 100 mg</title>
            <description>MSDC-0602 capsule 100 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>MSDC-0602 250 mg</title>
            <description>MSDC-0602 capsule 250 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>MSDC-0602 500 mg</title>
            <description>MSDC-0602 capsule 500 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 45 mg</title>
            <description>Pioglitazone capsule 45 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Molecular Weight Adiponectin</title>
          <description>To evaluate the effects of three different doses of MSDC-0602 and pioglitazone as compared to placebo on biomarkers of inflammatory status (high molecular weight adiponectin) following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.</description>
          <population>The Per-Protocol Population included all patients who completed the 4-week, double blind treatment period without any major deviations from the protocol procedures.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="15.28"/>
                    <measurement group_id="O2" value="44.1" spread="17.30"/>
                    <measurement group_id="O3" value="101.6" spread="17.00"/>
                    <measurement group_id="O4" value="139.2" spread="16.62"/>
                    <measurement group_id="O5" value="206.0" spread="16.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo capsule once daily</description>
        </group>
        <group group_id="E2">
          <title>MSDC-0602 100 mg</title>
          <description>MSDC-0602 capsule 100 mg once daily</description>
        </group>
        <group group_id="E3">
          <title>MSDC-0602 250 mg</title>
          <description>MSDC-0602 capsule 250 mg once daily</description>
        </group>
        <group group_id="E4">
          <title>MSDC-0602 500 mg</title>
          <description>MSDC-0602 capsule 500 mg once daily</description>
        </group>
        <group group_id="E5">
          <title>Pioglitazone 45 mg</title>
          <description>Pioglitazone capsule 45 mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jerry Colca, PhD</name_or_title>
      <organization>Metabolic Solutions Development Company</organization>
      <phone>269.343.6732</phone>
      <email>jcolca@msdrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

